Spyre Therapeutics (SYRE) has surged more than 565% over the past year, driven by strong technical momentum.
Shares are trading at a new 3-year high.
SYRE maintains a 100% "Buy" technical opinion from Barchart.
Short interest is elevated at 13.81% of float, highlighting volatility and the need for disciplined risk management.
Valued at $9.5 billion, Spyre Therapeutics (SYRE) is a biotechnology company which aims to create inflammatory bowel disease products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection.
#syre #technical #short #valued
Shares are trading at a new 3-year high.
SYRE maintains a 100% "Buy" technical opinion from Barchart.
Short interest is elevated at 13.81% of float, highlighting volatility and the need for disciplined risk management.
Valued at $9.5 billion, Spyre Therapeutics (SYRE) is a biotechnology company which aims to create inflammatory bowel disease products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection.
#syre #technical #short #valued
3 months ago
